On Friday, Shares of Umpqua Holdings Corporation (NASDAQ:UMPQ), dropped -1.00% to $16.84.
Umpqua Bank, a partner of Umpqua Holdings Corporation, declared that David Shotwell will step in as the company’s Chief Credit Officer following the retirement of Mark Wardlow, effective July 1, 2015.
Wardlow has been with Umpqua Bank for 11 years, serving as Executive Vice President and Chief Credit Officer since 2009. Shotwell also joined Umpqua Bank in 2004 and brings more than 30 years of expertise in both lending and credit administration to the position. He will continue the company’s focus on growing and strengthening Umpqua’s loan portfolio.
In his current role as Executive Vice President and Chief Lending Officer, Shotwell is responsible for credit administration and approval for commercial banking and commercial real estate within Umpqua’s five-state footprint. Before joining Umpqua, he worked for more than 20 years in the commercial banking and commercial real estate industry. He studied economics and finance at the University of Washington and is a graduate of executive programs at the University of California, Davis, and Pacific Coast Banking School.
Umpqua Holdings Corporation, through its auxiliaries, engages in the commercial and retail banking, and retail brokerage businesses. It operates through two segments, Community Banking and Home Lending. The Community Banking segment provides loan and deposit products to business and retail customers.
Shares of Noble Energy, Inc. (NYSE:NBL), declined -0.95% to $50.24, during its last trading session.
Noble Energy, declared that its Board of Directors has declared a quarterly cash dividend of 18 cents per common share payable on May 26, 2015 to the shareholders of record at the close of business on May 11, 2015.
Noble Energy, Inc., an independent energy company, engages in the acquisition, exploration, and production of crude oil, natural gas, and natural gas liquids worldwide. Its principal projects are located in onshore DJ Basin and Marcellus Shale, the United States; the deepwater Gulf of Mexico; offshore West Africa; and offshore Eastern Mediterranean.
At the end of Friday’s trade, Shares of Republic Services, Inc. (NYSE:RSG), dwindled -0.94% to $40.25.
Republic Services, declared a new landfill gas-to-energy (LFGTE) project located at Sunshine Canyon Landfill near Los Angeles. The 20-megawatt renewable energy project is capable of generating enough electricity to power nearly 25,000 area homes.
Republic Services partnered with Sunshine Gas Producers, a joint venture between DTE Biomass Energy and Aria Energy, to develop the Sunshine Canyon LFGTE project.
LFGTE projects typically involve capturing methane from biogas, which is generated by the decomposition of waste within a landfill. The methane is converted into renewable energy sources, in this case electricity that supplies the power grid. This process can displace the use of fossil fuels for energy generation and use, which can significantly reduce greenhouse gas emissions in a community.
According to the U.S. Environmental Protection Agency (EPA), LFGTE projects reduce reliance on non-renewable energy resources, such as coal or petroleum. The EPA estimates that three megawatts of energy produced from landfill gas is equivalent to preventing carbon emissions generated by the consumption of 16.6 million gallons of gasoline. Based on EPA calculations, the carbon emissions prevented by the new Sunshine Canyon LFGTE project from entering the air is equivalent to the consumption of more than 100 million gallons of gasoline.
Republic Services, Inc., together with its auxiliaries, provides non-hazardous solid waste collection, transfer, recycling, and disposal services for commercial, industrial, municipal, and residential customers in the United States. It operates through three segments: East, Central, and West.
Finally, Seattle Genetics, Inc. (NASDAQ:SGEN), ended its last trade with -0.90% loss, and closed at $34.03.
Seattle Genetics, stated financial results for the first quarter ended March 31, 2015. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization, regulatory and clinical development accomplishments, progress with other proprietary pipeline programs and antibody-drug conjugate (ADC) collaborator updates.
Recent ADCETRIS Highlights
- Declared that the U.S. Food and Drug Administration (FDA) filed the company’s supplemental BLA for use of ADCETRIS in the AETHERA setting for post-transplant consolidation treatment of Hodgkin lymphoma (HL) patients at high risk of relapse or progression. The FDA granted Priority Review and set a Prescription Drug User Fee Act (PDUFA) target action date of August 18, 2015.
- Received FDA approval for an amended SPA agreement for the phase 3 ECHELON-1 clinical trial in frontline HL. The amendment enhances target enrollment by 200 patients to a total of 1,240. To date, more than 1,000 patients have been enrolled on the trial and the company anticipates to complete enrollment in 2015. The timeline for reporting data from the ECHELON-1 trial continues to be in the 2017 to 2018 timeframe.
- Received FDA approval for an amended SPA agreement for the phase 3 ECHELON-2 clinical trial in frontline mature T-cell lymphoma (MTCL). The amendment enhances target enrollment by 150 patients to a total of 450. To date, nearly 300 patients have been enrolled on the trial and the company anticipates to complete enrollment in 2016. The timeline for reporting data from the ECHELON-2 trial continues to be in the 2017 to 2018 timeframe.
- Based on the AETHERA trial results, ADCETRIS was added to the National Comprehensive Cancer Network (NCCN) guidelines for up to one year of treatment in HL patients following autologous transplant who had primary refractory disease or who had relapsed less than 12 months following frontline therapy.
- Takeda Pharmaceutical Company Limited (Takeda) continues to receive additional marketing approvals for ADCETRIS, which is now commercially accessible in 55 countries worldwide. This is an enhance from 50 countries at the end of 2014.
ADCETRIS is not presently approved for use in frontline HL or MTCL or for the post-transplant consolidation treatment of HL patients at high risk of relapse or progression.
Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
